Chemistry:Inclacumab
From HandWiki
Short description: Monoclonal antibody
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | selectin P |
| Clinical data | |
| Other names | LC1004-002 |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6452H9930N1730O2024S42 |
| Molar mass | 145465.02 g·mol−1 |
Inclacumab (LC1004-002) (INN) is a human monoclonal antibody designed for the treatment of cardiovascular disease.[1][2][3][4][5][6][7][8][9]
The antibody is outlicensed by Roche.[10]
References
- ↑ World Health Organization (2011). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 106". WHO Drug Information 25 (4). https://www.who.int/medicines/publications/druginformation/innlists/Final_PL106.pdf.
- ↑ Statement On A Nonproprietary Name Adopted By The USAN Council - Inclacumab, American Medical Association.
- ↑ "Effects of the P-Selectin Antagonist Inclacumab on Myocardial Damage After Percutaneous Coronary Intervention According to Timing of Infusion: Insights From the SELECT-ACS Trial". J Am Heart Assoc 5 (11). November 2016. doi:10.1161/JAHA.116.004255. PMID 27852589.
- ↑ "Effects of P-Selectin Antagonist Inclacumab in Patients Undergoing Coronary Artery Bypass Graft Surgery: SELECT-CABG Trial". J. Am. Coll. Cardiol. 67 (3): 344–6. January 2016. doi:10.1016/j.jacc.2015.10.071. PMID 26796402.
- ↑ "Lack of ethnic differences in the pharmacokinetics and pharmacodynamics of inclacumab in healthy Japanese and Caucasian subjects". Eur. J. Clin. Pharmacol. 71 (11): 1365–74. November 2015. doi:10.1007/s00228-015-1938-4. PMID 26363899.
- ↑ "First-in-Man Study With Inclacumab, a Human Monoclonal Antibody Against P-selectin". J. Cardiovasc. Pharmacol. 65 (6): 611–9. June 2015. doi:10.1097/FJC.0000000000000233. PMID 25714598.
- ↑ "Absence of pharmacodynamic interaction between inclacumab and heparin in healthy smokers". J. Cardiovasc. Pharmacol. 65 (4): 386–92. April 2015. doi:10.1097/FJC.0000000000000211. PMID 25602360.
- ↑ "Effects of the P-selectin antagonist inclacumab on myocardial damage after percutaneous coronary intervention for non-ST-segment elevation myocardial infarction: results of the SELECT-ACS trial". J. Am. Coll. Cardiol. 61 (20): 2048–55. May 2013. doi:10.1016/j.jacc.2013.03.003. PMID 23500230.
- ↑ "Pharmacological control of platelet-leukocyte interactions by the human anti-P-selectin antibody inclacumab--preclinical and clinical studies". Thromb. Res. 131 (5): 401–10. May 2013. doi:10.1016/j.thromres.2013.02.020. PMID 23522853.
- ↑ "Form 8K - Entry into a Material Definitive Agreement Between Global Blood Therapeutics, Inc. and Hoffmann-La Roche Inc.". United States Securities and Exchange Commission. https://www.sec.gov/Archives/edgar/data/1629137/000117184318006225/f8k_082218.htm.
 |  |
